Canada Markets closed

Canntab Therapeutics Limited (CTABF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.09450.0000 (0.00%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0945
Open0.0945
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0945 - 0.0945
52 Week Range0.0945 - 0.6117
Volume10
Avg. Volume130
Market Cap3.872M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMar 08, 2016
1y Target EstN/A
  • CNW Group

    CANNTAB ANNOUNCES ITS ENTRANCE INTO THE NOVA SCOTIA CANNABIS MARKET

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to provide an update on its recent product delivery of our unique pharmaceutical cannabinoid solutions to the Nova Scotia Liquor Corporation (the "NSLC").

  • CNW Group

    CANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO

    Canntab Therapeutics Limited (CSE: PILL.CN)(OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022.

  • CNW Group

    Canntab Corporate Update

    Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the "Company" or "Canntab") a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing a corporate update to its shareholders and stakeholders. Further to the announcement made by Canntab on April 14, 2022 with respect to our exploration of a variety of alternative business strategies including potential M&A opportunities, as well as identifying and negotiating partnership